Anemia

Scientists Report Successful Erythropoietin Gene Delivery

Published in Gene Therapy Weekly, November 17th, 1997

Cell Genesys, Inc., Foster City, California, reported that a team of company scientists, led by Richard O. Snyder, Ph.D, has reported encouraging data in preclinical studies involving erythropoietin (Epo) gene therapy, a potential new treatment strategy for anemia.

In these studies, the Epo gene was delivered successfully to skeletal muscle tissue by using an adeno-associated viral (AAV) gene delivery system, or vector. These findings included prolonged expression of the delivered Epo gene for more than six months following just a single injection, stable production of the Epo protein, and effective gene delivery into non-dividing, adult muscle tissue. Taken...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry